Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer Ingelheim

Showing 15 posts of 116 posts found.

Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis

July 21, 2025
Medical Communications, Mergers and Acquisitions, Research and Development Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease

Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis …

News

Ochre Bio appoints Quin Wills as CEO to lead next phase of liver therapeutics development

June 30, 2025
Research and Development Boehringer Ingelheim, CEO, GSK, Hepatology, Ochre Bio, RNA therapeutics, chronic liver disease, clinical genomics

Oxford-based biotechnology company Ochre Bio has announced the appointment of Quin Wills as CEO. As co-founder of the company and …

Appointment

Boehringer Ingelheim acquires Nerio Therapeutics, strengthening immune-oncology profile

July 30, 2024
Mergers and Acquisitions Boehringer Ingelheim, Nerio Therapeutics, Oncology, immuno-oncology, oncology

Biopharmaceutical company Boehringer Ingelheim has announced the acquisition of drug discovery and development company Nerio Therapeutics for up to $1.3bn, …

News

Brainomix and Boehringer Ingelheim enter strategic partnership

July 19, 2024
Research and Development Boehringer Ingelheim, Brainomix, Pharmacy, fibrosing lung disease, partnership

Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for a collaborative programme surrounding the …

News

OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

May 24, 2024
Research and Development Boehringer Ingelheim, Cancer, Cardiology, OSE Immunotherapeutics, cardio-renal-metabolic diseases

OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership. The expansion includes two new projects …

News

Boehringer Ingelheim’s Spevigo gains additional approvals in US and China

March 20, 2024
Medical Communications Boehringer Ingelheim, Dermatology, FDA, Spevigo, psoriasis

Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and Drug Administration (FDA) for the …

News

Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment

February 26, 2024
Research and Development Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide

Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to …

News

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

September 25, 2023
Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …

News

Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal

May 9, 2023
Research and Development Boehringer Ingelheim, Rare Diseases, cell programming, ginkgo bioworks, undruggable targets

German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks have announced a partnership to …

News
boehringer_biberach_germany_copy

Researchers and pharma companies partner to investigate new schizophrenia treatment

January 21, 2021
Biogen, Boehringer Ingelheim

The University of Oxford, the Earlham Institute, and global pharmaceutical companies Biogen and Boehringer Ingelheim are partnering to investigate a …

News

Boehringer Ingelheim and Enara Bio to collaborate on cancer immunotherapies

January 12, 2021
Manufacturing and Production Boehringer Ingelheim, Cancer, Enara Bio

Boehringer Ingelheim and Enara Bio have entered into a strategic collaboration and licensing agreement to research and develop novel targeted …

News
boehringer_biberach_germany_copy

Boehringer’s nintedanib approved in Europe for systemic sclerosis-associated interstitial lung disease

April 22, 2020
Research and Development, Sales and Marketing Boehringer Ingelheim, EU, nintedanib, pharma

The European Commission has moved to authorise Boehringer Ingelheim’s nintedanib in Europe for the treatment of systemic sclerosis-associated interstitial lung …

News
jardiance-web

FDA advisory committee votes down approval of Boehringer and Lilly’s drug for type 1 diabetes

November 14, 2019
Sales and Marketing Boehringer Ingelheim, Eli Lilly, empagliflozin, jardiance, pharma

Boehringer Ingelheim and Eli Lilly’s have been dealt a blow from the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), …

News
boehringer_biberach_germany_copy

Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease

September 10, 2019
Manufacturing and Production, Sales and Marketing Boehringer Ingelheim, FDA, US, lungs, ofev, pharma, rare disease

Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of …

News
shutterstock_273326141

Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal

September 5, 2019
Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma

Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026